|
Florax®
Medication of biological origin, formed by suspension of Saccharomyces cerevisiae in natura. Researched by the Institute of Antibiotics of the Federal University of Pernambuco – UFPE. The great advantage of Saccharomyces cerevisiae FR 1972 bud is that, besides being a more active bud than other Saccharomyces, it displays all metabolites contained in the culture media, in its natural form. |
|
Giamebil®
Medication of phytotherapic origin, produced from Mentha crispa. Researched by the Institute of Antibiotics of the Federal University of Pernambuco – UFPE, Giamebil® holds proven efficiency in clinic tests, being compared to derived imidazoles, without their collateral effects. |
|
Imunoglucan®
Medication of biotechnological origin, this is a polysaccharide extracted from a yeast membrane. Research areas of the Federal University of Pernambuco – UFPE and the Department of Oncology of the Escola Paulista de Paulista and that of Federal University of São Paulo – UNIFESP were involved in the research. Imunoglucan® represents a landmark in Brazilian research. |
|
Kronel®
Medication of phytotherapic origin, the result of a research developed by the Pharmacy Laboratory of Federal University of Pernambuco. It has the Schinus terebinthifolius Raddy (Aroeira), a native plant of Brazilian Atlantic Forest as its active principle. |
Ansiopax
Piper methysticum Forst (kava-kava) |
Kronel Gel®
Medication of phytotherapic origin. It is a result of a research developed by the Pharmacy Laboratory of the Federal University of Pernambuco. It has the Schinus terebinthifolius Raddy (Aroeira), a native plant of Brazilian Atlantic Forest as its active principle. |
|
Melxi®
Medication of phytotherapic origin. Its active principle is Ananas comosus L, which associates in its composition, the enzymes with proteolytic activities; bromelain, ribonuclease, glucose-oxidase, invertase and diastase. Resulted from research performed by the Federal University of Pernambuco – UFPE and by the University of Pernambuco – UPE. |
|
Prostokos®
Synthetic analogous of Prostaglandin, developed by CEMICAMP/UNICAMP. Its use is restricted to hospitals. |
